KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Work In Process: 2011-2025

Historic Work In Process for Halozyme Therapeutics (HALO) over the last 13 years, with Sep 2025 value amounting to $34.8 million.

  • Halozyme Therapeutics' Work In Process rose 134.05% to $34.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year increase of 134.05%. This contributed to the annual value of $30.2 million for FY2024, which is 11.33% down from last year.
  • As of Q3 2025, Halozyme Therapeutics' Work In Process stood at $34.8 million, which was up 12.63% from $30.9 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Work In Process ranged from a high of $56.2 million in Q3 2022 and a low of $6.3 million during Q1 2022.
  • Moreover, its 3-year median value for Work In Process was $34.8 million (2025), whereas its average is $34.3 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Work In Process tumbled by 67.43% in 2022, and later spiked by 332.75% in 2023.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Work In Process stood at $17.5 million in 2021, then soared by 152.72% to $44.1 million in 2022, then dropped by 22.85% to $34.0 million in 2023, then dropped by 11.33% to $30.2 million in 2024, then spiked by 134.05% to $34.8 million in 2025.
  • Its last three reported values are $34.8 million in Q3 2025, $30.9 million for Q2 2025, and $36.7 million during Q1 2025.